Integrated proteomic analysis identifies four distinct subtypes of high-risk neuroblastoma
Kristin L. Leskoske, Sara A. Byron, Seema Plaisier, Apurva M. Hegde, Krystine Garcia-Mansfield, Ritin Sharma, Genevieve Bergendahl, Abhinav B. Nagulapally, William Ferguson, Jaqueline Kraveka, Javier Oesterheld, William P.D. Hendricks, Giselle[...]
A phase 1 dose escalation study of TB-403 in pediatric relapsed or refractory medulloblastoma, neuroblastoma, Ewing sarcoma or alveolar rhabdomyosarcoma
Giselle Saulnier Sholler, Dan G. Duda, Genevieve Bergendahl, David Ebb, Matija Snuderl, Theodore W. Laetsch, Jennifer Michlitsch, Derek Hanson, Michael S. Isakoff, Kevin Bielamowicz, Jacqueline Kraveka, Peter Carmeliet, Andy De[...]
Feasibility and applicability of molecular guided therapy in high grade glioma/diffuse midline glioma: Results from Beat Childhood Cancer NMTRC-009 Molecular Guided Therapy study
Virginia L. Harrod, MD, PhD, Abhinav B. Nagulapally, MS, Elizabeth C. Lewis, Giselle Saulnier Sholler, MD Feasibility and applicability of molecular guided therapy in high grade glioma/diffuse midline glioma: Results from[...]
Targeting Lin28 in ETMR with ODC1 inhibitor DFMO
Austin Goodyke, Shannon Kelly, Joseph Zagorski, Elizabeth VanSickle, Tyler Maser, Caryl Sortwell, Christopher Kemp, Abhinav Nagulapally, Karl Dykema, Giselle Saulnier-Sholler Targeting Lin28 in ETMR with ODC1 inhibitor DFMO, ISPNO 2020, Japan (Virtual)
The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma
Tyler Maser, Joseph Zagorski, Shannon Kelly, Anna Ostrander, Austin Goodyke, Abhinav Nagulapally, Jeffrey Bond, Yeonhee Park, Giselle Saulnier Sholler, The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell[...]
Multiple antibodies targeting tumor-specific mutations redirect immune cells to inhibit tumor growth and increase survival in experimental animal models
Shukla, G.S., S.C. Pero, Y. Sun, L. Mei, F. Zhang, G. Sholler, and D.N. Krag, Multiple antibodies targeting tumor-specific mutations redirect immune cells to inhibit tumor growth and increase survival in[...]
Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patients
Izhar S. Batth, Long Dao, Arun Satelli, Abhisek Mitra, Sofia Yi, Hyangsoon Noh, Heming Li, Zachary, Brownlee, Shouhao Zhou, Jeffrey Bond, Jing Wang, Jonathan Gill, Giselle S. Sholler, Shulin Li, Cell[...]
A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma
Elizabeth C. Lewis, Jacqueline M. Kraveka, William Ferguson, Don Eslin, Valerie I. Brown, Genevieve Bergendahl, William Roberts, Randal K. Wada, Javier Oesterheld, Deanna Mitchell, Jessica Foley, Peter Zage, Jawhar Rawwas,[...]
A collaborative pediatric cancer precision medicine model leveraging shared genomic, clinical, and research data from high-risk solid tumor patients across 45 clinical sites
Giselle L. Saulnier Sholler, Jacqueline M. Kraveka, William Ferguson, Genevieve Bergendahl, William P. D. Hendricks, Abhinav Nagulapally, Sara A. Byron, James Lowey, William Burleson, Elizabeth VanSickle, Muhammed Murtaza, Matija Snuderl,[...]
Maintenance DFMO Increases Survival in High Risk Neuroblastoma
Giselle L. Saulnier Sholler, William Ferguson, Genevieve Bergendahl, Jeffrey P. Bond, Kathleen Neville, Don Eslin, Valerie Brown, William Roberts, Randal K. Wada, Javier Oesterheld, Deanna Mitchell, Jessica Foley, Nehal S.[...]